BJ
MRNS

BlackRock Japan’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

BlackRock Japan’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-629
Closed -$19K – 1483
2015
Q4 		$19K Buy
+629
New +$18.4K ﹤0.01% 1170

Other funds holding MRNS

CPV
Canaan Partners VII Westport, Connecticut $32.3M AUM 154.97% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Japan's MRNS Position: Q1 2016 in Review

BlackRock Japan sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2016, closing a stake of 629 shares — an estimated $19K sold.

BlackRock Japan first reported a position in MRNS in Q4 2015 and held it in 1 quarter. The position peaked at $19K in Q4 2015. 31 funds tracked by Wall St. Rank hold MRNS as of Q1 2016.

  • BlackRock Japan reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2016 after selling out during the quarter.
  • BlackRock Japan sold 629 Marinus Pharmaceuticals, Inc shares in Q1 2016, an estimated $19K.
  • BlackRock Japan first reported a position in Marinus Pharmaceuticals, Inc in Q4 2015 and held it in 1 quarter.
  • BlackRock Japan's Marinus Pharmaceuticals, Inc position peaked at $19K in Q4 2015.
  • 31 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2016.

Based on BlackRock Japan's 13F filing for Q1 2016, filed 10 May 2016.